Motif Bio Share Discussion Threads

[miahkaysor] 10/4/2017 09:15

Good pick Fission ;-)

[fission453] 10/4/2017 08:33

Get in SRON quick!

I will only say it once!

[fission453] 10/4/2017 08:33

Off course mia!

[miahkaysor] 10/4/2017 08:30

35p next stop according to my chartist friend.

[cheshire man] 10/4/2017 08:28

Buyers out in force to start the week :-)

[miahkaysor] 10/4/2017 08:25

Can we break 30p today?? Psychological barrier?

[miahkaysor] 10/4/2017 03:07

I agree with above posts. I can see this hitting 50p this week and with positive newsflow re REVIVE, we could be trading anything between £1 - £1.50p!HUGE upside potential from current levels!!!!!!!All imho dyor etc.

[colebrooke] 09/4/2017 21:57

Motif Bio PLC logoEquities researchers at FinnCap began coverage on shares of Motif Bio PLC (LON:MTFB) in a research note issued on Tuesday. The brokerage set a "buy" rating and a GBX 125 ($1.56) price target on the stock. FinnCap's price objective suggests a potential upside of 376.19% from the stock's current price.A number of other equities analysts also recently weighed in on MTFB. Northland Securities dropped their target price on Motif Bio PLC from GBX 140 ($1.75) to GBX 90 ($1.12) and set a "buy" rating on the stock in a report on Wednesday, December 14th. Rodman & Renshaw initiated coverage on Motif Bio PLC in a report on Monday, January 9th. They issued a "buy" rating on the stock. Finally, Beaufort Securities reiterated a "speculative buy" rating and issued a GBX 110 ($1.37) target price on shares of Motif Bio PLC in a report on Wednesday, February 1st. Motif Bio PLC (LON:MTFB) opened at 26.75 on Tuesday. The firm's market capitalization is GBX 29.05 million. Motif Bio PLC has a 52-week low of GBX 21.44 and a 52-week high of GBX 68.25. The stock's 50 day moving average is GBX 25.02 and its 200-day moving average is GBX 31.14. Motif Bio PLC Company ProfileMotif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

[drmaccers] 09/4/2017 20:52

Big day tomorrow. Maybe 10%+

[drmaccers] 09/4/2017 10:09

So in all likelihood, REVIVE 1 results will be within a month. There have been various predictions of the COS with official conservative estimates of 85% and informed PIs (like myself) rating it above 90% All ducks are in a row here. There had been a big drop, long consolidation period, chart breakout, imminent results with the highest COS on AIM that if positive warrant an immediate 500-1000% rise on get anywhere near peers. I honestly don't see a better play on AIM currently. This drug has passed Phase 3 trials! It is now 30% more potent! Safety profile isn't an issue! Id be very surprised if there isn't a massive move towards 40-50p this week and £1.50+ when the good news comes in

[timbo003] 07/4/2017 14:18

The link to Graham Lumsden's presentation at the Master Investor show from a couple of weeks ago is now available:

[miahkaysor] 07/4/2017 12:49

Potential is HUGE!!!!!

[miahkaysor] 07/4/2017 12:48

50p by Monday!!

[miahkaysor] 07/4/2017 12:44

That's my 90k!

[tilly99] 07/4/2017 12:33

These will get to 100p look at prtk

[deanmatlazin] 07/4/2017 10:15

This is a no brainer. The trial finished end of January. I am sure the directors knew the preliminary result and one of them bought £442000 worth of shares and the other bought £260000 worth of shares a week after the trial finished.

I am pretty confident that the outcome will be positive.

The question is...

How much this company will be valued at for an antibiotic to penetrate $3billion market segment????

[timbo003] 07/4/2017 10:03

I believe the chances of the two studies meeting the primary end points are 90% or greater and the chances of obtaining FDA approval will be roughly the same.

The real question is what will be the eventual labeling and warnings which come with the approvals in the US, Europe and elsewhere. It is these details (which differentiate Iclaprim from the current SOC) which will determine whether the product is a commercial success.

[small crow] 07/4/2017 09:49

75% chance of approval, best guess?

[nick rubens] 07/4/2017 09:32

Upside looks immense on FDA approval. How much the market will price it up before knowing for certain is another matter.

[essential] 07/4/2017 09:19

Mirabeau - good post

[essential] 07/4/2017 09:01

Don't fight the technicals- breakout on huge volume - fundamentals will always fill the void...

[qazwsxedc69] 07/4/2017 09:00

I got in here at circa 25p only last week. Would love to claim myself as a genius, but purely luck to get in before this recent and welcome rise. This company strikes me as not dissimilar to one of my faves IMM i.e. awaiting Phase 3 results and a likely binary outcome of multi bagging or virtual bust.

I was attracted in particular now as I thought this was at the stage where share price drifts slowly lower on a lack of news and results.

Great to see all the information posted in the header above and I am slowly working through some of it, but would welcome any pointers towards any articles/info that are particularly recommended.

[small crow] 07/4/2017 08:54

"No more reason for a rise this week than there has been for 6 months."

Well, except much closer to clinical trial results with, consequentially, shorts closing (plus perhaps the end of whatever complex financial shenanigans surrounded the IPO)?

[letmepass] 07/4/2017 08:51

Agree, Nice bowl though and volume.. Looks good for medium term hold